Omeros Corporation today announced the availability on its website of materials accompanying two presentations given at the 2025 Tandem Meetings ? the Transplantation & Cellular Therapy Meetings of ...
Immunocompromised patients undergoing hematopoietic stem cell transplants (HSCTs) who have a reported penicillin allergy should be evaluated as the allergy label limits access to preferred antibiotics ...
Hematopoietic stem cell transplantation (HSCT) is a vital treatment for both malignant and non-malignant disorders in pediatric patients.
Elixirgen Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of rare diseases and aging-associated diseases using its ZSCAN4 technology and mRNA platform ...
Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the ...
Rocket Pharmaceuticals, Inc.'s innovative therapies show promise after FDA setbacks. With potential $1B+ markets, RCKT offers ...
Dana-Farber Cancer Institute researchers will present key research studies at the 2025 Tandem Meetings, the premier ...
Dana-Farber Cancer Institute researchers will present key research studies at the 2025 Tandem Meetings, the premier conference in hematopoietic cell transplantation (HCT) and cellular therapy.
Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.
Mair Therapeutics Secures Pre-Seed Funding and Launches to Pioneer Therapies for Parkinson's Disease
Torrey Pines Investment, a specialty life-science investment company based in San Diego, CA, and Oost NL, a regional development agency supporting innovation-driven companies, announced the pre-seed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback